Pharmacotherapy: concepts of pathogenesis and emerging treatments. Challenges in clinical trial design in inflammatory arthritis.
The prognosis for patients with rheumatoid arthritis has improved dramatically, thanks in large part to many new therapies and therapeutic approaches. Paradoxically, this has created problems for rheumatologists since clinically useful information from appropriate clinical trials has not kept pace with all the new therapeutic options. Essentially, rheumatologists now have many more therapeutic options than they know what to do with. This article discusses why we are in this situation and suggests opportunities to move forward.
O'Dell
James R
JR
Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska 68198-3025, USA. jrodell@unmc.edu
D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000209:etiology* / Q000628:therapy*; D002986:Clinical Trials as Topic / Q000191:economics / Q000379:methods; D004359:Drug Therapy, Combination; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D012107:Research Design; D012219:Rheumatology / Q000379:methods* / Q000639:trends
D018501:Antirheumatic Agents; D007166:Immunosuppressive Agents